RxDoctor Payments Data

Jeffrey Bergeson

Optometrist · Kingman, AZNPI 1861691586

Payments from drug & device makers

$1,234in general payments, 2019–2025

Across 46 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$305
  • Sight Sciences, Inc.$172
  • Bausch & Lomb Americas Inc.$170
  • Optos, Inc.$128
  • Sun Pharmaceutical Industries Inc.$121
  • AbbVie$117
  • plus $220 from 8 others

What the payments were for

  • Food & beverage$1,12191%
  • Entertainment$1139%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,234 in reported general payments places this provider in the 60th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$141,486
Medicare patients
654
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost81$42,826
RocklatanNetarsudil Mesylat/Latanoprost23$21,668
Cyclosporine15$12,830
CombiganBrimonidine Tartrate/Timolol24$7,830
Travoprost31$7,034
Latanoprost465$5,844
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$5,180
Brinzolamide17$4,576
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat107$2,296
SimbrinzaBrinzolamide/Brimonidine Tart12$2,274
Fluorometholone15$1,776
Brimonidine Tartrate46$1,423
Prednisolone Acetate37$1,244
Timolol Maleate104$1,126
Dorzolamide Hcl42$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$117$50,655105 claims
Aerie Pharmaceuticals, Inc.Rocklatan$44$21,66823 claims
AlconSimbrinza$305$2,27412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Kingman

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →